Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea

被引:16
作者
Ahn, So-Hyeon [1 ,2 ]
Choi, Nam-Kyong [3 ,4 ]
Kim, Ye-Jee [1 ,2 ]
Seong, Jong-Mi [1 ,2 ]
Shin, Ju-Young [1 ,2 ]
Jung, Sun-Young [1 ,2 ]
Park, Byung-Joo [1 ,2 ]
机构
[1] Korea Inst Drug Safety & Risk Management, Seoul, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul 110799, South Korea
[3] Seoul Natl Univ, Seoul Natl Univ Hosp, Div Clin Epidemiol, Med Res Collaborating Ctr,Coll Med, Seoul 110799, South Korea
[4] Seoul Natl Univ, Med Res Ctr, Seoul 110799, South Korea
关键词
Medication persistence; Dementia; Alzheimer type; Cholinesterase inhibitors; Pharmacoepidemiology; Elderly; DISEASE; DONEPEZIL; EFFICACY; THERAPY; SAFETY; COSTS;
D O I
10.1007/s12272-014-0500-8
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study examined 1-year persistency with cholinesterase inhibitors (ChEIs) for the treatment of elderly Alzheimer's dementia (AD) patients in Korea. Korean Health Insurance Review & Assessment Service database from January 2005 to June 2006 was used. Patients aged 65 or older with AD diagnosis who were first prescribed a ChEI were included. The 1-year persistence, persistency rate, and switching patterns during the follow-up period were identified. Mean time to drug discontinuation was analyzed, and persistency rates between different patient factors were compared. The 1-year persistency rate of newly treated 6,461 AD patients was 24.0 %, while 50 % of study patients discontinued treatment by 91 days from initiation. Persistency rates of female patients (22.8 %), patients in rural areas (12.7 %), and primary care (10.2 %) were relatively low (p < 0.001). Persistency rate differed between age groups (p < 0.001). Overall proportion of switching was 6.6 %. The 1-year persistency rate of ChEIs for AD patients in Korea did not reach those of previous researches in other countries. Patients less likely to remain on therapy should be especially monitored to optimize treatment persistence.
引用
收藏
页码:1255 / 1262
页数:8
相关论文
共 33 条
[1]  
Abughosh Susan M, 2008, Patient Prefer Adherence, V2, P79
[2]  
Alzheimer's Association, 2010, Alzheimers Dement, V6, P158, DOI 10.1016/j.jalz.2010.01.009
[3]  
Alzheimer's Disease International, 2012, WORD ALZH REP 2012
[4]   Persistence with cholinesterase inhibitor therapy in a population based cohort of patients with Alzheimer's disease [J].
Amuah, Joseph E. ;
Hogan, David B. ;
Eliasziw, Misha ;
Supina, Alison ;
Beck, Patricia ;
Downey, Winanne ;
Maxwell, Colleen J. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (07) :670-679
[5]  
[Anonymous], 2003, Adherence to Long-Term Therapies: Evidence for action
[6]  
[Anonymous], NATIONWIDE STUDY PRE
[7]   A population-based study of dosing and persistence with anti-dementia medications [J].
Brewer, Linda ;
Bennett, Kathleen ;
McGreevy, Cora ;
Williams, David .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (07) :1467-1475
[8]   DOCUMENTATION AND EVALUATION OF COGNITIVE IMPAIRMENT IN ELDERLY PRIMARY-CARE PATIENTS [J].
CALLAHAN, CM ;
HENDRIE, HC ;
TIERNEY, WM .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (06) :422-429
[9]  
Cummings JL, 2002, AM FAM PHYSICIAN, V65, P2525
[10]   Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease [J].
Doody, RS ;
Geldmacher, DS ;
Gordon, B ;
Perdomo, CA ;
Pratt, RD .
ARCHIVES OF NEUROLOGY, 2001, 58 (03) :427-433